Arrowhead Added to PowerShares Lux Nanotech Exchange Traded Fund
"The Lux Nanotech Index aims to be comprehensive for nanotech specialists, including all firms that meet our eligibility criteria for market valuation, trading volume, and listing on a major U.S. exchange. Arrowhead now meets these criteria," stated Matthew M. Nordan, co-chair of the Index selection committee, in the firm's press release.
“We are pleased to be included among this exclusive list of companies developing nanotechnology and that, of the 26 companies included on the Index, Arrowhead currently has the highest weighting based upon its recent performance”
"We are pleased to be included among this exclusive list of companies developing nanotechnology and that, of the 26 companies included on the Index, Arrowhead currently has the highest weighting based upon its recent performance," stated Dr. Leon Ekchian, President of Arrowhead.
Exchange-traded funds (ETFs) are baskets of securities designed to replicate the performance of a stock or bond index (e.g., Dow Jones Industrial Average, S&P 500). ETFs are listed on an exchange and can be traded intra-day at a price set by the market. ETFs are designed to add the flexibility, ease, and liquidity of stock trading to the benefits of traditional index fund investing.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy.
There are three strategic components to Arrowhead's business model:
-- Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a highly cost-effective development pipeline. Currently, Arrowhead is supporting efforts in stem cell technology, and nanosensors at the California Institute of Technology and Stanford University.
-- Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial, and operational support. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials and carbon nanotube technologies.
-- The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company is actively seeking to add to this intellectual property portfolio.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.